News
6h
Stocktwits on MSNNurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead PaymentsShares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the ...
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...
Shares of Nurix Therapeutics rose after the biopharmaceutical company reported that revenue in its fiscal second quarter more than tripled from a year ago. The stock was up 11%, at $14.59, in ...
Nonetheless, the firm concluded that Kymera’s partnerships with Sanofi and Gilead continue to “drive value.” Don't miss out ...
The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.
US antivirals specialist Gilead Sciences today announced a strategic partnership agreement with the Global Fund to Fight AIDS ...
Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results